BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 10454455)

  • 1. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
    Brown NJ; Agirbasli M; Vaughan DE
    Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.
    Brown NJ; Agirbasli MA; Williams GH; Litchfield WR; Vaughan DE
    Hypertension; 1998 Dec; 32(6):965-71. PubMed ID: 9856958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension.
    Sakata K; Pawlak R; Urano T; Takada A
    Pathophysiol Haemost Thromb; 2002; 32(2):67-75. PubMed ID: 12214151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
    Brown NJ; Kumar S; Painter CA; Vaughan DE
    Hypertension; 2002 Dec; 40(6):859-65. PubMed ID: 12468570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
    Goodfield NE; Newby DE; Ludlam CA; Flapan AD
    Circulation; 1999 Jun; 99(23):2983-5. PubMed ID: 10368114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoreceptor blockers and angiotensin-converting enzyme inhibitors.
    Sayer JW; Gutteridge C; Syndercombe-Court D; Wilkinson P; Timmis AD
    J Am Coll Cardiol; 1998 Dec; 32(7):1962-8. PubMed ID: 9857879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension.
    Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S
    Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
    Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
    Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.
    Leenen FH; White R; Yuan B
    Am J Physiol Heart Circ Physiol; 2001 Dec; 281(6):H2410-6. PubMed ID: 11709406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
    Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ
    J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women.
    Fogari R; Zoppi A; Preti P; Fogari E; Malamani G; Mugellini A
    Am J Hypertens; 2001 Sep; 14(9 Pt 1):921-6. PubMed ID: 11587159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H
    Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
    Gainer JV; Morrow JD; Loveland A; King DJ; Brown NJ
    N Engl J Med; 1998 Oct; 339(18):1285-92. PubMed ID: 9791144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-angiotensin system inhibition on noradrenergic nerve terminal function in pacing-induced heart failure.
    Kawai H; Stevens SY; Liang CS
    Am J Physiol Heart Circ Physiol; 2000 Dec; 279(6):H3012-9. PubMed ID: 11087259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolytic function in diuretic-induced volume depletion.
    Lottermoser K; Hertfelder HJ; Vetter H; Düsing R
    Am J Hypertens; 2000 Apr; 13(4 Pt 1):359-63. PubMed ID: 10821336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
    Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between chronic converting enzyme inhibition and AT1 blockade in mRen2 transgenic rats.
    Lantelme P; Lo M; Mullins JJ; Gharib C; Bizollon CA; Sassard J
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):476-81. PubMed ID: 8847862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients.
    Matsumoto T; Minai K; Horie H; Ohira N; Takashima H; Tarutani Y; Yasuda Y; Ozawa T; Matsuo S; Kinoshita M; Horie M
    J Am Coll Cardiol; 2003 Apr; 41(8):1373-9. PubMed ID: 12706934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
    Hu K; Gaudron P; Anders HJ; Weidemann F; Turschner O; Nahrendorf M; Ertl G
    Cardiovasc Res; 1998 Aug; 39(2):401-12. PubMed ID: 9798525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis.
    Erlinger TP; Conlin PR; Macko RF; Bohannon AD; Miller ER; Moore TJ; Svetkey LP; Appel LJ
    J Hum Hypertens; 2002 Jun; 16(6):391-7. PubMed ID: 12037693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.